Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy

被引:75
作者
Bergwitz, Clemens [1 ]
Miyamoto, Ken-Ichi [2 ]
机构
[1] Yale Univ, Sch Med, Sect Endocrinol & Metab, Anlyan Ctr,Off S117,Lab S110, 1 Gilbert St, New Haven, CT 06519 USA
[2] Tokushima Univ, Grad Sch Biomed Sci, Dept Mol Nutr, Tokushima, Japan
来源
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY | 2019年 / 471卷 / 01期
关键词
Rickets; Hypophosphatemia; HHRH; NPT2c; SLC34A3; Osteoporosis; Nephrolithiasis; Nephrocalcinosis; Renal phosphate-wasting; Hyperphosphaturia; PHOSPHATE COTRANSPORTER GENE; NA/PI-COTRANSPORTER; PARATHYROID-HORMONE; IDIOPATHIC HYPERCALCIURIA; ONCOGENIC OSTEOMALACIA; PROXIMAL TUBULOPATHY; INTRONIC DELETIONS; MISSENSE MUTATION; RENAL EXPRESSION; NHERF1; MUTATIONS;
D O I
10.1007/s00424-018-2184-2
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Hereditary hypophosphatemic rickets with hypercalciuria (HHRH; OMIM: 241530) is a rare autosomal recessive disorder with an estimated prevalence of 1:250,000 that was originally described by Tieder et al. Individuals with HHRH carry compound-heterozygous or homozygous (comp/hom) loss-of-function mutations in the sodium-phosphate co-transporter NPT2c. These mutations result in the development of urinary phosphate (Pi) wasting and hypophosphatemic rickets, bowing, and short stature, as well as appropriately elevated 1,25(OH)(2)D levels, which sets this fibroblast growth factor 23 (FGF23)-independent disorder apart from the more common X-linked hypophosphatemia. The elevated 1,25(OH)(2)D levels in turn result in hypercalciuria due to enhanced intestinal calcium absorption and reduced parathyroid hormone (PTH)-dependent calcium-reabsorption in the distal renal tubules, leading to the development of kidney stones and/or nephrocalcinosis in approximately half of the individuals with HHRH. Even heterozygous NPT2c mutations are frequently associated with isolated hypercalciuria (IH), which increases the risk of kidney stones or nephrocalcinosis threefold in affected individuals compared with the general population. Bone disease is generally absent in individuals with IH, in contrast to those with HHRH. Treatment of HHRH and IH consists of monotherapy with oral Pi supplements, while active vitamin D analogs are contraindicated, mainly because the endogenous 1,25(OH)(2)D levels are already elevated but also to prevent further worsening of the hypercalciuria. Long-term studies to determine whether oral Pi supplementation alone is sufficient to prevent renal calcifications and bone loss, however, are lacking. It is also unknown how therapy should be monitored, whether secondary hyperparathyroidism can develop, and whether Pi requirements decrease with age, as observed in some FGF23-dependent hypophosphatemic disorders, or whether this can lead to osteoporosis.
引用
收藏
页码:149 / 163
页数:15
相关论文
共 148 条
[1]   Clinical and genetic characteristics of 15 families with hereditary hypophosphatemia: Novel Mutations in PHEX and SLC34A3 [J].
Acar, Sezer ;
Bin Essai, Huda A. ;
Demir, Korcan ;
Al-Rijjal, Roua A. ;
Zou, Minjing ;
Catli, Gonul ;
Anik, Ahmet ;
Al-Enezi, Anwar F. ;
Ozisik, Secil ;
Al-Faham, Manar S. A. ;
Abaci, Ayhan ;
Dundar, Bumin ;
Kattan, Walaa E. ;
Alsagob, Maysoon ;
Kavukcu, Salih ;
Tamimi, Hamdi E. ;
Meyer, Brian F. ;
Bober, Ece ;
Shi, Yufei .
PLOS ONE, 2018, 13 (03)
[2]   ASSESSMENT AND INTERPRETATION OF THE TUBULAR THRESHOLD FOR PHOSPHATE IN INFANTS AND CHILDREN [J].
ALON, U ;
HELLERSTEIN, S .
PEDIATRIC NEPHROLOGY, 1994, 8 (02) :250-251
[3]   FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway [J].
Andrukhova, Olena ;
Zeitz, Ute ;
Goetz, Regina ;
Mohammadi, Moosa ;
Lanske, Beate ;
Erben, Reinhold G. .
BONE, 2012, 51 (03) :621-628
[4]  
[Anonymous], 2000, NAT GENET, V26, P345
[5]   Anti-FGF-23 Neutralizing Antibodies Ameliorate Muscle Weakness and Decreased Spontaneous Movement of Hyp Mice [J].
Aono, Yukiko ;
Hasegawa, Hisashi ;
Yamazaki, Yuji ;
Shimada, Takashi ;
Fujita, Toshiro ;
Yamashita, Takeyoshi ;
Fukumoto, Seiji .
JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (04) :803-810
[6]   Idiopathic Calcium Nephrolithiasis: A Review of Pathogenic Mechanisms in the Light of Genetic Studies [J].
Arcidiacono, Teresa ;
Mingione, Alessandra ;
Macrina, Lorenza ;
Pivari, Francesca ;
Soldati, Laura ;
Vezzoli, Giuseppe .
AMERICAN JOURNAL OF NEPHROLOGY, 2014, 40 (06) :499-506
[7]   Kidney-specific inactivation of the megalin gene impairs trafficking of renal inorganic sodium phosphate cotransporter (NaPi-IIa) [J].
Bachmann, S ;
Schlichting, U ;
Geist, B ;
Mutig, K ;
Petsch, T ;
Bacic, D ;
Wagner, CA ;
Kaissling, B ;
Biber, J ;
Murer, H ;
Willnow, TE .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (04) :892-900
[8]   The renal Na+/phosphate cotransporter NaPi-IIa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone [J].
Bacic, D ;
LeHir, M ;
Biber, J ;
Kaissling, B ;
Murer, H ;
Wagner, CA .
KIDNEY INTERNATIONAL, 2006, 69 (03) :495-503
[9]   Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders [J].
Bai, XY ;
Miao, DS ;
Li, JR ;
Goltzman, D ;
Karaplis, AC .
ENDOCRINOLOGY, 2004, 145 (11) :5269-5279
[10]   Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities [J].
Beck, L ;
Karaplis, AC ;
Amizuka, N ;
Hewson, AS ;
Ozawa, H ;
Tenenhouse, HS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :5372-5377